Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
9.68
-0.28 (-2.81%)
At close: Sep 12, 2025, 4:00 PM EDT
9.87
+0.19 (1.96%)
After-hours: Sep 12, 2025, 7:00 PM EDT

Cartesian Therapeutics Stock Forecast

Stock Price Forecast

The 4 analysts that cover Cartesian Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $40, which forecasts a 313.22% increase in the stock price over the next year. The lowest target is $38 and the highest is $42.

Price Target: $40 (+313.22%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$38$40$40$42
Change+292.56%+313.22%+313.22%+333.88%
* Price targets were last updated on Jul 9, 2025.

Analyst Ratings

The average analyst rating for Cartesian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingApr '25May '25Jun '25Jul '25Aug '25Sep '25
Strong Buy666443
Buy100111
Hold111000
Sell000000
Strong Sell000000
Total877554

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Wedbush
Wedbush
Buy
Initiates
$38
BuyInitiates$38+292.56%Jul 9, 2025
Needham
Needham
Strong Buy
Maintains
$41$40
Strong BuyMaintains$41$40+313.22%May 8, 2025
Needham
Needham
Strong Buy
Reiterates
$41
Strong BuyReiterates$41+323.55%Apr 9, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$40
Strong BuyReiterates$40+313.22%Apr 9, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$45$40
Strong BuyMaintains$45$40+313.22%Mar 14, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
1.90M
from 38.91M
Decreased by -95.11%
Revenue Next Year
535.50K
from 1.90M
Decreased by -71.86%
EPS This Year
-2.18
from -4.49
EPS Next Year
-3.63
from -2.18
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
85.08M110.78M26.00M38.91M1.90M535.50K528.77K
Revenue Growth
-30.21%-76.53%49.64%-95.11%-71.86%-1.26%
EPS
-6.742.98-49.76-4.49-2.18-3.63-3.90
EPS Growth
-------
Forward PE
-------
No. Analysts
----11117
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High5.3M1.7M
Avg1.9M535,500
Low1.1Mn/a

Revenue Growth

Revenue Growth20252026202720282029
High
-86.5%
-11.7%
Avg
-95.1%
-71.9%
Low
-97.2%
-

EPS Forecast

EPS20252026202720282029
High-1.54-2.19
Avg-2.18-3.63
Low-3.43-4.41

EPS Growth

EPS Growth20252026202720282029
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.